Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + 5-azacytidine in Pediatric Relapsed/Refractory AML
NCT03825367Phase 2Unknown
- Sponsor
- Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium
- Start
- Nov 2019
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in acute myeloid leukemia (AML), sponsored by Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium. Status: unknown.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03825367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825367.